# Narration and storyboard draft: Retatrutide: Clinical Weight Loss and Supply Claims

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Retatrutide has a real clinical weight-loss effect. That is what the supervised randomized trials demonstrate. It is a different question whether all three hormone receptors are required in people, whether it beats modern obesity-dose semaglutide or tirzepatide, and whether a vial bought online reproduces trial quality. The2023phase2study established large placebo-controlled loss over48weeks. BySeptember2026, peer-reviewedTRIUMPHresults extended the picture to80weeks in adults with and withoutdiabetes. Our Consensus cross-check missed those new results, so we corrected its timeline against the originalrecords. Metabolic biomarkers and appetite questionnaires add leads; they do not replace receptor-partition experiments or hard clinical outcomes. The next informative study is a matched active comparison with retatrutide-specific maintenance and withdrawal data. Productquality needs its own identified-batch testing and clinical bridge. We rate trial-defined efficacy separately from those broader claims.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.